Date: 2014-12-10
Type of information: Presentation of results at a congress
phase:
Announcement: presentation of results at the 20th World Congress on Controversies in Obstetrics, Gynecology & Infertility in Paris
Company: Roche (Switzerland)
Product: Elecsys® preeclampsia test
Action
mechanism: The Elecsys preeclampsia test measures two proteins sFlt-1 (soluble fms-like tyrosine kinase-1) and PlGF (placental growth factor) in maternal blood. Depending on the test result, which is reflected as a ratio of the two proteins, physicians can reliably exclude or predict the development the disease short-term, confidently focus on those women at high risk of preeclampsia.
Disease: preeclampsia
Therapeutic area: Women health
Country:
Trial
details: * On December 10, 2014, Roche announced that results of the PROGNOSIS study presented at the 20th World Congress on Controversies in Obstetrics, Gynecology & Infertility in Paris, demonstrate the prognostic value of the Elecsys® preeclampsia test from Roche to predict the absence of preeclampsia for one week and the development of preeclampsia within the subsequent four weeks. The test result enables healthcare professionals to avoid unnecessary hospitalizations by reliably ruling out preeclampsia for one week and to improve outcome for mother and child by ruling in preeclampsia allowing optimized prenatal care. Preeclampsia is defined by hypertension associated with an increased amount of protein in the urine (proteinuria). Other clinical symptoms of preeclampsia can include severe headache, sudden swelling of face, hands and feet and pain in the upper abdomen. However, both hypertension and proteinuria are poor in predicting the clinical onset of the disease and its progression.
Latest news:
